NCT07171515

Development & Clinical Application of K-PaC Registry Version 2.0

• Status: Enrolling By Invitation
• Phase: —
• Study type: Observational
• Enrollment: 6,923 (estimated)
• Sponsor: National Cancer Center, Korea · Other Government
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

Development and clinical use of pancreatic cancer registry * Development of K-PaC Registry v.2.0: Retrospective data integration from 2010 to 2022 and prospective data collection from more than 811 enrolled patients from 2023 to 2029 * Creation of clinical evidence (RWE) based on pancreatic cancer real-world data (RWD): 3 or more

Detailed description

We plan to collect retrospective and prospective data based on medical data centered on EMR. ∙ This registry is built on EMR data containing specific information on medical provider records and patient health records. It is designed to enable the confirmation of specific treatment history and medical staff records, and to generate highly valid RWD-based evidence through EMR information such as accurate diagnosis of disease, treatment method, symptom changes, monitoring of lab data values, and patient status. ∙ Based on the built registry data, it is possible to conduct research based on evaluation of drug treatment and additional comparison of indications for elderly or poor general condition patients who are excluded from regular clinical trials, as well as research on diagnosis and prognosis. The clinical information and biomarkers of the prospective patient group are analyzed to evaluate the correlation with treatment response, overall and progression-free survival rates.

Conditions

• Pancreatic Cancer

Timeline

• Start date: 2023-01-02
• Primary completion: 2029-12-31
• Completion: 2030-12-31
• First posted: 2025-09-12
• Last updated: 2025-09-12

Locations

1 site across 1 country: South Korea